APPENDIX

Answers for multiple-choice questions on diagnosis and treatment of invasive fungal infections*.

Item

CANDIDIASIS

Difference between colonization and infection by Candida species

- 1. Which of the following answers best describes what you would do when faced with *Candida* isolated in a urine culture?
- a) Systematically start antifungal treatment in all cases.
- b) Start antifungal treatment if the colony count is >10⁴ cfu/ml.
- c) Start antifungal treatment if the colony count is >10⁵ cfu/ml.
- d) Start antifungal treatment if the patient has a urinary catheter.
- e) Start antifungal treatment only in specific cases.
- 2. In a patient undergoing mechanical ventilation and with probable ventilator-associated pneumonia (VAP), a tracheal aspirate culture was positive for *Candida* species. Which of the following statements best expresses your interpretation?
- a) This is a case of colonization; therefore, no antifungal treatment is needed.
- b) Start treatment with fluconazole, since it is VAP caused by Candida.
- c) Start treatment with an echinocandin, since the VAP was caused by Candida.
- d) Start antifungal treatment only if the patient has a high Candida score.
- e) Start antifungal treatment if the Candida count is >10⁵ cfu/ml.

Candida prophylaxis

- 3. In which of the following clinical scenarios would you start Candida prophylaxis?
- a) ICU patient colonized by Candida.
- b) ICU patient not colonized by *Candida* but with a urinary catheter, central venous catheter, and recent surgery.
- c) Liver transplant recipients with no other risk factors.
- d) Acute myeloid leukemia patients on induction chemotherapy.
- e) All of the above.
- 4. In your opinion, which of the following is the best choice for *Candida* prophylaxis?
- a) Fluconazole in most cases.
- b) Candins.
- c) Liposomal amphotericin B.
- d) Voriconazole.
- e) None of the above.

Empirical treatment for candidemia

- 5. In a patient with sepsis possibly caused by a femoral catheter infection, which of the following would you prescribe?
- a) Treatment against Gram-positive bacteria.
- b) Treatment against Gram-positive and Gram-negative bacteria.
- c) Treatment against Gram-positive and Gram-negative bacteria and yeasts.

- d) Treatment against Gram-negative bacteria.
- e) None of the above. I would remove the catheter and wait for the culture results before starting antifungals.
- 6. A microbiologist informs you that there are yeasts in the gram stain of a blood culture. Which of the following apply to you?
- a) You start antifungal treatment immediately.
- b) You wait to see how many bottles it grows in.
- c) You wait for the final microbiological identification.
- d) You remove the catheters and take new blood cultures.
- e) You request cryptococcal serology testing.
- 7. In a patient with candidemia without severe sepsis, which antifungal agent would be your first choice before knowing the species of *Candida*?
- a) I would wait for the full identification of the microorganism before starting any antifungal agent.
- b) Voriconazole.
- c) An echinocandin or fluconazole.
- d) Liposomal amphotericin B.
- e) Posaconazole.

Targeted treatment of candidemia

- 8. Which of the following statements is correct?
- a) Candida glabrata can become resistant to fluconazole.
- b) Candida krusei is always resistant to fluconazole.
- c) Candida parapsilosis is associated with catheter infection.
- d) Candida albicans is usually susceptible to fluconazole.
- e) All of the above.
- 9. What is the percentage of fluconazole resistance in *Candida* strains isolated from blood cultures at your hospital?
- a) Less than 5%.
- b) Between 5% and 10%.
- c) Between 10% and 20%.
- d) Between 20% and 30%.
- e) Over 30%.
- 10. In the treatment of candidemia caused by a fluconazole-susceptible *Candida* species, which of the following would you usually prescribe?
- a) Caspofungin 70 mg on the first day and then 50 mg daily.
- b) Fluconazole 200 mg daily.
- c) Fluconazole 400-800 mg per day depending on the Candida species.
- d) More than 800 mg of fluconazole daily.
- e) None of the above.

- 11. During the follow-up of candidemic patients, which of the following are recommended?
- a) Obtain blood cultures after 3-7 days of antifungal treatment.
- b) Rule out infective endocarditis by systematic transesophageal echocardiography.
- c) Consider sequential treatment by switching to an oral azole.
- d) Perform funduscopy.
- e) All of the above.

Indications for amphotericin B, azoles, and candins

- 12. In which of the following scenarios would L-AmB be your first choice?
- a) In the empirical treatment of candidemia.
- b) In proven invasive aspergillosis.
- c) In unspecified invasive filamentous fungal infection.
- d) In patients who are intolerant of fluconazole.
- e) In infections due to fluconazole-resistant Candida.
- 13. Which of the following statements is true for treatment with azoles and candins?
- a) Candins can be used as empirical treatment before the antifungal susceptibility of a yeast is known.
- b) Voriconazole is used to treat infections caused by fluconazole-resistant *Candida* and is preferred to a candin.
- c) Since voriconazole has no significant interactions with other drugs, it is preferred to a candin.
- d) Candins are superior to fluconazole in the treatment of candidemia due to fluconazole-susceptible species.
- e) Posaconazole is the first choice for fluconazole-resistant Candida.

INVASIVE ASPERGILLOSIS

Difference between colonization and infection by Aspergillus species

- 14. When *Aspergillus* species is isolated in a respiratory sample, which of the following approaches would you take?
- a) Always start antifungal treatment.
- b) Always start treatment in immunosuppressed patients.
- c) Treat only when the patient has radiological findings in the thoracic CT scan.
- d) Treat when the fungal invasion is confirmed by biopsy.
- e) Treat patients who fulfilled the criteria for proven or probable invasive aspergillosis.

Diagnosis of invasive aspergillosis

- 15. Which of the following statements regarding the galactomannan test is false?
- a) It is highly sensitive for neutropenic patients with invasive aspergillosis (cut-off >0.5).
- b) The test has a low sensitivity in solid organ transplant recipients.
- c) Patients receiving some antibiotics could have false-positive test results.

- d) It helps in the follow-up of antifungal treatment.
- e) It can only be performed in serum samples.
- 16. Which of the following are considered radiological findings of invasive aspergillosis?
- a) Presence of dense, well-circumscribed lesions with or without a halo sign in a thoracic CT scan.
- b) Presence of a cavity in a thoracic CT scan.
- c) Presence of an air-crescent sign in a thoracic CT scan.
- d) Sinusitis.
- e) All of the above.

Monitoring of antifungal drug level and treatment of aspergillosis

- 17. In a patient with invasive pulmonary aspergillosis, which antifungal treatment would you choose before antifungal susceptibility data were available?
- a) Voriconazole.
- b) Voriconazole + caspofungin.
- c) Liposomal amphotericin B 3 mg/kg/d.
- d) Amphotericin B + voriconazole.
- e) Liposomal amphotericin B 10 mg/kg/d.
- 18. What is your opinion on determination of antifungal levels?
- a) Up-to-date guidelines do not recommend systematic determination.
- b) It can help to detect underdosing.
- c) There is no indication for determination of serum levels of liposomal amphotericin B.
- d) It can help to identify azole-related toxicity.
- e) All of the above.
- 19. In your opinion, which are the indications for combined antifungal therapy in invasive aspergillosis?
- a) Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.
- b) Invasive pulmonary aspergillosis in neutropenic patients or transplant recipients.
- c) Combination therapy is not supported by clinical evidence (clinical trials).
- d) Combination therapy can prove useful in cases associated with non-fumigatus Aspergillus species.
- e) It can only be used as rescue therapy when previous antifungal treatment has failed.
- 20. In your opinion, which is the correct duration of treatment for solid organ transplant recipients?
- a) 2 weeks.
- b) 4-6 weeks.
- c) A minimum of 6-12 weeks.
- d) 3-6 months.

e) More than 6 months.

*The correct answer is marked in bold.